DE69706657D1 - Natürliches menschliches alpha interferon enthaltende pharmazeutische zusammensetzungen - Google Patents

Natürliches menschliches alpha interferon enthaltende pharmazeutische zusammensetzungen

Info

Publication number
DE69706657D1
DE69706657D1 DE69706657T DE69706657T DE69706657D1 DE 69706657 D1 DE69706657 D1 DE 69706657D1 DE 69706657 T DE69706657 T DE 69706657T DE 69706657 T DE69706657 T DE 69706657T DE 69706657 D1 DE69706657 D1 DE 69706657D1
Authority
DE
Germany
Prior art keywords
natural human
human alpha
pharmaceutical compositions
compositions containing
containing natural
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69706657T
Other languages
English (en)
Other versions
DE69706657T2 (de
Inventor
Giulio Tarro
Renzo Brozzo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Unihart Corp
Original Assignee
Unihart Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ITRM960136 external-priority patent/IT1283945B1/it
Priority claimed from IT96RM000427 external-priority patent/IT1284852B1/it
Application filed by Unihart Corp filed Critical Unihart Corp
Application granted granted Critical
Publication of DE69706657D1 publication Critical patent/DE69706657D1/de
Publication of DE69706657T2 publication Critical patent/DE69706657T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69706657T 1996-02-28 1997-02-27 Natürliches menschliches alpha interferon enthaltende pharmazeutische zusammensetzungen Expired - Fee Related DE69706657T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITRM960136 IT1283945B1 (it) 1996-02-28 1996-02-28 Uso dell'interferone alfa naturale umano da cellule linfoblastoidi per la terapia delle epatiti virali, neoplasie e sindromi da
IT96RM000427 IT1284852B1 (it) 1996-06-14 1996-06-14 Uso dell'interferone alfa naturale umano da cellule leucocitarie per la terapia delle epatiti virali, neoplasie e sindromi da
PCT/IT1997/000040 WO1997031649A1 (en) 1996-02-28 1997-02-27 PHARMACEUTICAL COMPOSITIONS COMPRISING NATURAL HUMAN α-INTERFERON

Publications (2)

Publication Number Publication Date
DE69706657D1 true DE69706657D1 (de) 2001-10-18
DE69706657T2 DE69706657T2 (de) 2002-06-20

Family

ID=26332096

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69706657T Expired - Fee Related DE69706657T2 (de) 1996-02-28 1997-02-27 Natürliches menschliches alpha interferon enthaltende pharmazeutische zusammensetzungen

Country Status (14)

Country Link
US (1) US6884411B1 (de)
EP (1) EP0886527B1 (de)
JP (1) JP2000506839A (de)
KR (1) KR100394382B1 (de)
AT (1) ATE205397T1 (de)
AU (1) AU722987B2 (de)
BR (1) BR9707772A (de)
DE (1) DE69706657T2 (de)
DK (1) DK0886527T3 (de)
EA (1) EA001147B1 (de)
ES (1) ES2160927T3 (de)
GE (1) GEP20012489B (de)
PT (1) PT886527E (de)
WO (1) WO1997031649A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004022593A2 (en) * 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
ITMI20030826A1 (it) * 2003-04-18 2004-10-19 Unihart Corp Composizione farmaceutica contenente interferone per il
ES2303492A1 (es) * 2004-08-18 2008-08-01 Instituto Cientifico Y Tecnologico De Navarra S.A. Uso del factor de crecimiento semejante a la insulina tipo i y de interferon alfa en el tratamiento de una enfermedad hepatica cronica, kit y composiciones que los comprenden.
WO2006032711A1 (es) * 2004-08-18 2006-03-30 Instituto Científico Y Tecnológico De Navarra S.A. Uso del factor de crecimiento semejante a la insulina tipo i y de interferón alfa en el tratamiento de una enfermedad hepática crónica, kit y composiciones que los comprenden
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA878295B (en) * 1986-11-06 1988-05-03 Amarillo Cell Culture Co. Inc. Treatment of immuno-resistant disease
CA1320905C (en) * 1986-11-06 1993-08-03 Joseph M. Cummins Treatment of immuno-resistant disease
TW224053B (de) * 1991-09-13 1994-05-21 Paul B Chretien
US6387365B1 (en) * 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection
US5980884A (en) * 1996-02-05 1999-11-09 Amgen, Inc. Methods for retreatment of patients afflicted with Hepatitis C using consensus interferon
HUP9602024A3 (en) * 1996-07-25 1999-05-28 Toth Sandor Pharmaceutical composition containing aminoacid for external use

Also Published As

Publication number Publication date
KR100394382B1 (ko) 2004-02-05
GEP20012489B (en) 2001-07-25
EP0886527B1 (de) 2001-09-12
EP0886527A1 (de) 1998-12-30
US6884411B1 (en) 2005-04-26
JP2000506839A (ja) 2000-06-06
DE69706657T2 (de) 2002-06-20
ES2160927T3 (es) 2001-11-16
AU2229997A (en) 1997-09-16
AU722987B2 (en) 2000-08-17
EA199800770A1 (ru) 1999-02-25
KR19990082559A (ko) 1999-11-25
ATE205397T1 (de) 2001-09-15
WO1997031649A1 (en) 1997-09-04
DK0886527T3 (da) 2002-03-04
BR9707772A (pt) 2000-01-04
EA001147B1 (ru) 2000-10-30
PT886527E (pt) 2001-12-28

Similar Documents

Publication Publication Date Title
AR012614A1 (es) Una composicion farmaceutica para la fabricacion de un medicamento destinado para el tratamiento de una infeccion viral susceptible de tratamientocon interferon alfa, un metodo para la fabricacion de un medicamento, el uso de peg12000-ifn alfa para la fabricacion de un medicamento
DK0911033T4 (da) Anvendelse af konsensusinterferon til reduktion af bivirkningerne af interferonbehandling i viral hepatitis
DK0871748T3 (da) Indgivelse af biologisk aktive polypeptider
HUP0101293A2 (hu) AspB28-humán inzulint tartalmazó inhalációs gyógyászati készítmény és alkalmazása
ATE165000T1 (de) Dosierungsform zur verzoegerten wirkstofffreisetzung
MX171191B (es) Composiciones farmaceuticas de glipizida
ITRM910922A1 (it) Composizione farmaceutica anticefalalgica per somministrazione endonasale, procedimento per prepararla e suo impiego terapeutico
DK0527835T3 (da) Doseringsform til afgivelse af et anti-Parkinsonmiddel
BRPI0108435B8 (pt) formulação e uso de entecavir de baixa dose
HUP0102033A2 (hu) PEG IFN-alfa és ribavirin felhasználása krónikus hepatitis C kezelésére
HUP0103423A2 (hu) Ribavirint és alfa-interferont tartalmazó kombinált terápia vírusellenes kezelésben nem részesült, krónikus hepatitis C fertőzött paciensek kezelésében
AU7589587A (en) Low dosage of interferon to enhance vaccine efficiency
RU92016463A (ru) Применение производных цистина для изготовления лекарственных препаратов с иммуномоделирующим действием, фармацевтические композиции на их основе
ATE205397T1 (de) Natürliches menschliches alpha interferon enthaltende pharmazeutische zusammensetzungen
HK1041215A1 (en) Use of thymosin alpha 1 in combination with lamivudine or in combination with lamivudine and famciclovir in manufacturing pharmaceutical combination preparations for treating hepatitis b infection.
BR0108997A (pt) Terapia imune adjuvante para hiv
AU2880595A (en) Use of pharmaceutical agents for restoring, alleviation, or treatment of immunodeficiency, including the alleviation or treatment of the immune dysfunction related to infection with human immunodeficiency viruses (hiv) or related viruses
ATE43498T1 (de) Pyrethroid enthaltende pharmazeutische zubereitungen.
KR960700741A (ko) 인터페론치료에 대한 무응답자의 c형 간염 치료방법(method of treating hepatitis c in non-pesponders to interferon treatment)
OA08768A (fr) Traitement du virus su SIDA par l'interféron alpha humain recombinant.
ATE348628T1 (de) Behandlung von hepatitis c mit thymosin, interferon und ribavirin
IT1283945B1 (it) Uso dell'interferone alfa naturale umano da cellule linfoblastoidi per la terapia delle epatiti virali, neoplasie e sindromi da
IT1284852B1 (it) Uso dell'interferone alfa naturale umano da cellule leucocitarie per la terapia delle epatiti virali, neoplasie e sindromi da
HUP9902188A2 (hu) Természetes humán alfa-interferont tartalmazó gyógyszerkészítmények
Prescott Lamivudine useful against hepatitis B-HIV co-infection

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee